Browse > Article

Pulmonary Thromboembolism after Post-menopause Hormonal Replacement Therapy  

Kim, Sun Young (Department of Internal Medicine, Inje University)
Park, Jong Hyeok (Department of Internal Medicine, Inje University)
Lee, Hyun Kyung (Department of Internal Medicine, Inje University)
Lee, Hyuk Pyo (Department of Internal Medicine, Inje University)
Lee, Hye Kyung (Department of Pathology, Inje University)
Choi, Soo Jeon (Department of Internal Medicine, Inje University)
Yum, Ho-Kee (Department of Internal Medicine, Inje University)
Publication Information
Tuberculosis and Respiratory Diseases / v.63, no.4, 2007 , pp. 362-367 More about this Journal
Abstract
Hormonal replacement therapy (HRT) has been proven for treatment of postmenopausal symptoms such as hot flushes, night sweats and urologic symptoms. HRT became very popular in the 1990's, when there were several reports showing that it also helped with other menopausal complications such as osteoporosis and cardiovascular disease. Recent studies report that the incidence of breast cancer, endometrial cancer, cerebral infarction, coronary artery diseases, deep vein thrombosis and pulmonary thrombembolism could rise after HRT. Among these side effects of HRT, the risk of pulmonary thromboembolism increases 2 to 4 fold after HRT, but can vary with the use of different doses and preparations. Here, we summarize the risk factors and clinical courses for 5 patients who developed pulmonary thromboembolism after postmenopausal HRT.
Keywords
Postmenopause hormone replacement therapy(HRT); Pulmonary thromboembolism; Deep vein thrombosis;
Citations & Related Records

Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Barlow DH. Hormone replacement therapy and the risk of deep vein thrombosis. Int J Gynecol Obstet 1997;59:S29-S33   DOI   ScienceOn
2 Gerstman EB, Piper JJM, Tomita DK, Ferguoon WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991;133:32-7   DOI
3 Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996;348:977-80   DOI   ScienceOn
4 Vessay M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboemholism: findings in a large prospective study. Br Med J 1983;292:526   DOI
5 Gerstman BB, Piper JM, Freiman JP, Tomita DR, Kennedy DL, Ferguson WJ, et al. Oral contruceptive estrogen and progestin potencies and the incidence of deep venous thromboembolism. Int J Epidemiol 1990;19:931-6   DOI
6 Lidegaard O, Edstrim B, Kreiner S. Oral contraceptives and venous thromboemholism. A case-control study. Contraception 1998;57:291-301   DOI   ScienceOn
7 Jick H, Derby LE, Myers MW, Vasi!akis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1993;348:931-3
8 Scarahin PY, Oger E, Plu-Bureau G. Differential association of oral and transderkmal oestmgen-replacement therapy with venous thromboemholism risk. Lancet 2003;362:428-32   DOI
9 Bae SJ, Kim JS, Kim JH, Yun YJ, Lee SA A case of venous thrombosis developed in a woman taking oral contraceptives with antithrombin III, protein C and protein 8 deficiencies. Korean J Obstet Gynecol 2003;49:1383-8
10 Douketis JD, Julian JA, Keamn C, Anderson DR, Crowther MA, Bates SM, et al. The, the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study. J Thromh Haemost 2005;3:943-8   DOI   ScienceOn
11 Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy. JAMA 2002;288:872-81   DOI   ScienceOn
12 Wu O. Pbstmenopausal hormone replacement therapy and venous thromboembolism. Gender Medicine 2005;2:S18-S27   DOI   ScienceOn